Pharmaceutical patent term restoration analysis
Evaluated the net benefits associated with granting patent term restoration for a brand-name pharmaceutical for which the US Patent and Trademark Office did not grant such extension. Work resulted in a white paper that updated a previous CBO legislative scoring document. The analysis focused on the likely benefits associated with continued marketing and the resulting expanded use of the brand-name drug in terms of improved clinical outcomes relative to existing therapies.